Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration

Intensive Care Medicine

Volumn 29, Issue 10, 2003, Pages 1844-1848

  Yagasaki, Kazuaki ^a   Gando, Satoshi ^b   Matsuda, Naoyuki ^b   Kameue, Takashi ^b   Ishitani, Toshiteru ^b   Hirano, Takeshi ^a   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antifungal; Continuous hemodiafiltration; Critically ill patient; Fluconazole; Immunocompromised host; Pharmacokinetic

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INTENSIVE CARE UNIT; MALE; MYCOSIS; PROSPECTIVE STUDY; STEADY STATE;

ADULT; AGED; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; FEMALE; FLUCONAZOLE; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0242677656     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1980-z     Document Type: Article

References (14)

1. Rex JH, Bennett JE, Sugar AM, Pappas PG, Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331:1325-1330
2. Berl T, Wilner KD, Gardner M, Hansen RA, Farmer B, Baris BA, Henrich WL (1995) Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 6:242-247
3. Debruyne D, Ryckelynck JP, Moulin M, Hurault de Ligny B, Levaltier B, Bigot MC (1990) Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 8:491-498
4. Kishino S, Koshinami Y, Hosoi T, Suda N, Takekuma Y, Gandoh S, Furukawa H, Todo S, Miyazaki K (2001) Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. Ther Drug Monit 23:4-8
5. Muhl E, Martens T, Iven H, Rob P, Bruch HP (2000) Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 56:671-678
6. Debruyne D (1997) Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33:52-77
7. Grant SM, Clissold SP (1990) Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916
8. Cociglio M, Brandissou S, Alric R, Bressolle F (1996) High-performance liquid Chromatographic determination of fluconazole in plasma. J Chromatogr B Biomed Appl 686:11-17
9. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharm Dyn 4:879-885
10. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA (1997) Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 41:1392-1395
11. 18F- labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 37:1270-1277
12. Shrikhande S, Friess H, Issenegger C, Martignoni ME, Yong H, Gloor B, Yeates R, Kleeff J, Büchler MW (2000) Fluconazole penetration into the pancreas. Antimicrob Agents Chemother 44:2569-2571
13. Hughes CE, Bennett RL, Tuna IC, Beggs WH (1988) Activities of fluconazole (UK 49:858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother 32:209-212
14. Debruyne D, Ryckelynck JP (1993) Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 24:10-27